SciQuest gives customers full control over chemical inventory with latest ERM upgrade
![](/46/pdcnewsitem/04/24/11/sciquest.png)
Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine.
SciQuest, a leading provider of spend management solutions delivering value beyond savings, has released the latest version of Enterprise Reagent Manager (ERM), the only chemical inventory management software that gives researchers and scientists full and efficient control over research inventory from sourcing and purchase through tracking and disposal.
Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine, complete with real-time material availability check from suppliers, which allows search across all internal and external sources simultaneously. Through this robust capability, users can now search chemicals by supplier, chemical structure or text description to better meet their research needs.
With near instant startup, ERM 9 is up to 90 percent faster than previous versions. The dynamic and responsive user interface contains one-click tiles for quick navigation to important tasks and status icons that remain with use and display user actions, like items adding to a shopping cart or requesting a container for use from inventory. With the most modern UI that SciQuest has ever developed, ERM is adapted for the tablets and workstations most widely used in today’s research environments.
In addition to the federated search, the ERM 9 upgrade includes the following features:
Held Cart: Allows administrators to control purchases of high cost and/or hazardous materials from non-authorized personnel
“Since ERM closely integrates with procurement, pharmaceutical manufacturers can control complex inventories with reduced general spend and disposal costs, optimized inventory use, and increased regulatory compliance while managing the risks associated with hazardous materials,” said Stephen Wiehe, president and CEO of SciQuest. “With the first and only triple federated search, ERM is so powerful that it even allows the user to start taking action or look up specific information on displayed results, while continuing to receive results for more applicable chemicals or building block compounds.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance